85 related articles for article (PubMed ID: 24513148)
1. Identification of novel small molecule inhibitors of activated protein C.
Sperandio O; Wildhagen KC; Schrijver R; Wielders S; Villoutreix BO; Nicolaes GA
Thromb Res; 2014 Jun; 133(6):1105-14. PubMed ID: 24513148
[TBL] [Abstract][Full Text] [Related]
2. An exosite-specific ssDNA aptamer inhibits the anticoagulant functions of activated protein C and enhances inhibition by protein C inhibitor.
Müller J; Isermann B; Dücker C; Salehi M; Meyer M; Friedrich M; Madhusudhan T; Oldenburg J; Mayer G; Pötzsch B
Chem Biol; 2009 Apr; 16(4):442-51. PubMed ID: 19389630
[TBL] [Abstract][Full Text] [Related]
3. Zinc ions bind to and inhibit activated protein C.
Zhu T; Ubhayasekera W; Nickolaus N; Sun W; Tingsborg S; Mowbray SL; Schedin-Weiss S
Thromb Haemost; 2010 Sep; 104(3):544-53. PubMed ID: 20664913
[TBL] [Abstract][Full Text] [Related]
4. Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by alpha(1)-antitrypsin.
Glasscock LN; Gerlitz B; Cooper ST; Grinnell BW; Church FC
Biochim Biophys Acta; 2003 Jun; 1649(1):106-17. PubMed ID: 12818196
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of thrombin formation by active site mutated (S360A) activated protein C.
Nicolaes GA; Bock PE; Segers K; Wildhagen KC; Dahlbäck B; Rosing J
J Biol Chem; 2010 Jul; 285(30):22890-900. PubMed ID: 20484050
[TBL] [Abstract][Full Text] [Related]
6. Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin.
Shen L; Dahlbäck B; Villoutreix BO
Biochemistry; 2000 Mar; 39(11):2853-60. PubMed ID: 10715104
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Lys 62(217) and Lys 63(218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor.
Shen L; Villoutreix BO; Dahlbäck B
Thromb Haemost; 1999 Jul; 82(1):72-9. PubMed ID: 10456457
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C.
Gale AJ; Tsavaler A; Griffin JH
J Biol Chem; 2002 Aug; 277(32):28836-40. PubMed ID: 12063259
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.
Bach P; Knerr L; Fjellström O; Hansson K; Mattsson C; Gustafsson D
Bioorg Med Chem Lett; 2014 Feb; 24(3):821-7. PubMed ID: 24418773
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.
Andreou AP; Efthymiou M; Yu Y; Watts HR; Noormohamed FH; Ma D; Lane DA; Crawley JT
PLoS One; 2015; 10(4):e0122410. PubMed ID: 25830552
[TBL] [Abstract][Full Text] [Related]
11. Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C.
Friedrich U; Blom AM; Dahlbäck B; Villoutreix BO
J Biol Chem; 2001 Jun; 276(26):24122-8. PubMed ID: 11316800
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics and docking simulation of a natural variant of Activated Protein C with impaired protease activity: implications for integrin-mediated antiseptic function.
D'Ursi P; Orro A; Morra G; Moscatelli M; Trombetti G; Milanesi L; Rovida E
J Biomol Struct Dyn; 2015; 33(1):85-92. PubMed ID: 24251463
[TBL] [Abstract][Full Text] [Related]
13. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S.
van Wijnen M; Stam JG; van't Veer C; Meijers JC; Reitsma PH; Bertina RM; Bouma BN
Thromb Haemost; 1996 Sep; 76(3):397-403. PubMed ID: 8883277
[TBL] [Abstract][Full Text] [Related]
14. Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.
Berg DT; Gerlitz B; Shang J; Smith T; Santa P; Richardson MA; Kurz KD; Grinnell BW; Mace K; Jones BE
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4423-8. PubMed ID: 12671072
[TBL] [Abstract][Full Text] [Related]
15. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va.
Nishioka J; Ido M; Hayashi T; Suzuki K
Thromb Haemost; 1996 Feb; 75(2):275-82. PubMed ID: 8815576
[TBL] [Abstract][Full Text] [Related]
16. The heparin binding site of protein C inhibitor is protease-dependent.
Li W; Huntington JA
J Biol Chem; 2008 Dec; 283(51):36039-45. PubMed ID: 18974053
[TBL] [Abstract][Full Text] [Related]
17. Factor Va, bound to microparticles released during platelet storage, is resistant to inactivation by activated protein C.
Magdeleyns EJ; Keuren JF; Curvers J
Transfusion; 2007 Oct; 47(10):1880-8. PubMed ID: 17880615
[TBL] [Abstract][Full Text] [Related]
18. Novel toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening.
Švajger U; Brus B; Turk S; Sova M; Hodnik V; Anderluh G; Gobec S
Eur J Med Chem; 2013; 70():393-9. PubMed ID: 24177366
[TBL] [Abstract][Full Text] [Related]
19. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition.
Dahlbäck B; Villoutreix BO
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1311-20. PubMed ID: 15860736
[TBL] [Abstract][Full Text] [Related]
20. Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va.
Friedrich U; Nicolaes GA; Villoutreix BO; Dahlbäck B
J Biol Chem; 2001 Jun; 276(25):23105-8. PubMed ID: 11309403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
